JPMorgan lowered the firm’s price target on Evolent Health (EVH) to $7 from $13 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $9 from $16 at Canaccord
- Evolent Health: Strong Growth Prospects and Strategic Market Positioning Justify Buy Rating
- Evolent Health: Positioned for Growth with Strong Fundamentals and Valuation Upside
- Evolent Health upgraded to Overweight at Stephens with sentiment near bottom
- Evolent Health upgraded to Overweight from Equal Weight at Stephens